Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00790660 · ClinicalTrials.gov registry record · Phase 2

A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus.

A Phase 2 study, sponsored by Astellas Pharma.

Completed
Registry status
Phase 2
Development phase
61
Enrollment target

NCT00790660 is a Phase 2 study that has completed, run by Astellas Pharma. The registered enrollment target is 61 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00790660, a Phase 2 study, has completed, sponsored by Astellas Pharma.

COMPLETED
Registry status
Phase 2
Development phase
61 participants
Enrollment target

Study Summary

This study is intended to assess safety and tolerability of ASP1941 compared to placebo in adult subjects with type 2 diabetes mellitus

Interventions

  • DRUG Placebo
  • DRUG ASP1941

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2008-10-23
Est. Completion 2009-03-06
Phase Phase 2

Sponsor

Astellas Pharma

165 total trials

What the Registry Record Tells You About NCT00790660

The ClinicalTrials.gov registry entry for NCT00790660 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00790660 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00790660 about?

NCT00790660 is a clinical study titled "A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus.". This study is intended to assess safety and tolerability of ASP1941 compared to placebo in adult subjects with type 2 diabetes mellitus

What is the current status of trial NCT00790660?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2008-10-23. Estimated completion is 2009-03-06.

What interventions are being tested in trial NCT00790660?

The interventions under investigation include: Placebo (DRUG), ASP1941 (DRUG).

Who is sponsoring clinical trial NCT00790660?

This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.